Add like
Add dislike
Add to saved papers

MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway.

OBJECTIVE: STAT3 is an important protein in Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway that facilitates B-cell lymphoma 2 (Bcl-2) expression. MiR-17 was found to be significantly reduced in prostate cancer tissues and cells, suggesting that it might be a tumor suppressor in prostate cancer tumorigenesis. Bioinformatics analysis showed the complementary binding site between miR-17 and STAT3. This study aimed to investigate the role of miR-17 in regulating JAK-STAT signaling pathway, as well as prostate cancer cell proliferation and apoptosis.

MATERIALS AND METHODS: Dual luciferase assay was used to verify the targeted relationship between miR-155 and STAT3. LNCaP cells were cultured in vitro and divided into four groups, including mimic NC, miR-17 mimic, si-NC, and si-STAT3 groups. STAT3, p-STAT3, and Bcl-2 expressions were tested by western blot. Cell apoptosis was detected by flow cytometry. Cell proliferation was assessed by EdU staining.

RESULTS: MiR-17 mimic transfection significantly reduced the relative luciferase activity in HEK293T cells. MiR-17 targeted regulated STAT3 expression. MiR-17 expression and cell apoptosis were obviously declined, while STAT3 level and cell proliferation markedly were elevated in LNCaP cells compared with RWPE-1 cells. MiR-17 mimic and/or si-STAT3 transfection significantly downregulated the expression of STAT3, p-STAT3, and Bcl-2, attenuated cell proliferation, and enhanced cell apoptosis in LNCaP cells.

CONCLUSIONS: Upregulation of miR-17 inhibited LNCaP cell proliferation and induced cell apoptosis by downregulating the expression of STAT3, p-STAT3, and Bcl-2.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app